NewAmsterdam Pharma Company N.V.
NAMS
$36.47
-$3.98-9.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 762.15% | 586.97% | 223.37% | 78.77% | -65.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 762.15% | 586.97% | 223.37% | 78.77% | -65.24% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 762.15% | 586.97% | 223.37% | 78.77% | -65.24% |
| SG&A Expenses | 85.49% | 88.86% | 87.19% | 85.84% | 78.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.57% | 15.29% | 12.58% | 21.80% | 35.22% |
| Operating Income | 17.20% | 4.46% | 3.65% | -15.11% | -50.71% |
| Income Before Tax | 27.75% | 18.06% | -36.57% | -20.19% | -46.66% |
| Income Tax Expenses | -103.70% | -103.70% | -103.70% | -- | -- |
| Earnings from Continuing Operations | 27.76% | 18.07% | -36.54% | -20.20% | -46.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.76% | 18.07% | -36.54% | -20.20% | -46.68% |
| EBIT | 17.20% | 4.46% | 3.65% | -15.11% | -50.71% |
| EBITDA | 17.26% | 4.51% | 3.69% | -15.09% | -50.70% |
| EPS Basic | 39.89% | 31.27% | -19.63% | 90.74% | 94.30% |
| Normalized Basic EPS | 41.77% | 31.01% | -13.16% | 90.80% | 94.22% |
| EPS Diluted | 39.89% | 31.27% | -19.63% | 90.75% | 94.31% |
| Normalized Diluted EPS | 41.77% | 31.01% | -13.16% | 90.80% | 94.22% |
| Average Basic Shares Outstanding | 23.23% | 20.76% | 14.80% | 45.38% | 108.34% |
| Average Diluted Shares Outstanding | 23.23% | 20.76% | 14.80% | 45.38% | 108.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |